These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 16912518

  • 1. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K.
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [Abstract] [Full Text] [Related]

  • 2. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations.
    Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, Kanamaru M, Hiratsuka A, Watabe T, Uematsu T.
    Clin Cancer Res; 2005 Jul 15; 11(14):5104-11. PubMed ID: 16033824
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J, Adleff V, Hitre E, Pap E, Réti A, Komlósi V, Budai B.
    Magy Onkol; 2007 Jul 15; 51(2):113-25. PubMed ID: 17660867
    [Abstract] [Full Text] [Related]

  • 4. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB.
    Eur J Cancer; 2004 May 15; 40(7):939-50. PubMed ID: 15093568
    [Abstract] [Full Text] [Related]

  • 5. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U, Farese S, Aebi S, Largiadèr CR.
    J Exp Clin Cancer Res; 2008 Oct 20; 27(1):54. PubMed ID: 18937829
    [Abstract] [Full Text] [Related]

  • 6. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH, Lee AM, Mattison LK, Diasio RB.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [Abstract] [Full Text] [Related]

  • 7. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
    Lazar A, Jetter A.
    Dtsch Med Wochenschr; 2008 Jul 15; 133(28-29):1501-4. PubMed ID: 18597209
    [Abstract] [Full Text] [Related]

  • 8. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
    Coriat R, Chaussade S.
    Therapie; 2007 Jul 15; 62(2):105-9. PubMed ID: 17582310
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K.
    Int J Clin Oncol; 2003 Jun 15; 8(3):132-8. PubMed ID: 12851836
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Höffken K.
    Clin Cancer Res; 2001 Sep 15; 7(9):2832-9. PubMed ID: 11555601
    [Abstract] [Full Text] [Related]

  • 14. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.
    Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, Kidouchi K, Togari H, Wada Y.
    Clin Cancer Res; 1998 Dec 15; 4(12):2999-3004. PubMed ID: 9865912
    [Abstract] [Full Text] [Related]

  • 15. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
    Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, Meindl A, Schmitt M, Kiechle M.
    Hum Mutat; 2003 Dec 15; 22(6):498. PubMed ID: 14635116
    [Abstract] [Full Text] [Related]

  • 16. Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer.
    Yu Z, Yang Q, Sun J, Zhen J.
    Exp Oncol; 2007 Sep 15; 29(3):192-6. PubMed ID: 18004243
    [Abstract] [Full Text] [Related]

  • 17. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z, Zhang R, Diasio RB.
    Cancer Res; 1993 Nov 15; 53(22):5433-8. PubMed ID: 8221682
    [Abstract] [Full Text] [Related]

  • 18. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
    Lee A, Ezzeldin H, Fourie J, Diasio R.
    Clin Adv Hematol Oncol; 2004 Aug 15; 2(8):527-32. PubMed ID: 16163233
    [Abstract] [Full Text] [Related]

  • 19. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B.
    Ther Drug Monit; 2006 Oct 15; 28(5):678-85. PubMed ID: 17038885
    [Abstract] [Full Text] [Related]

  • 20. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
    Milano G, Etienne MC.
    Anticancer Res; 1994 Oct 15; 14(6A):2295-7. PubMed ID: 7825962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.